Source: Health Canada shortage reports · Updated Jul 17, 2026
Also sold as: Movisse, Micronor, Maeve, Jencycla
Some Norethindrone products are in shortage in Canada (1 of 4 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
A progestin hormone used for birth control and menstrual conditions.
Products affected
1 / 4
In shortage since
Dec 1, 2025
Reports on file
13
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
MAEVE
0.35MG · TABLET · GLENMARK PHARMACEUTICALS CANADA INC.
DIN 02458683 · since Dec 1, 2025, no end estimate · Disruption of the manufacture of the drug.
Resolved
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Jul 6, 2022 · Disruption of the manufacture of the drug.
Resolved
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Dec 30, 2021 · Demand increase for the drug.
To be discontinued
MICRONOR TABLETS 28-DAY
0.35MG · TABLET · JANSSEN INC
DIN 00037605
To be discontinued
MICRONOR TABLETS 28-DAY
0.35MG · TABLET · JANSSEN INC
DIN 00037605
Resolved
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Apr 28, 2020 · Demand increase for the drug.
Resolved
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Feb 25, 2020 · Delay in shipping of the drug.
Resolved
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Jan 22, 2020 · Delay in shipping of the drug.
Resolved
JENCYCLA
0.35MG · TABLET · LUPIN PHARMA CANADA LIMITED
DIN 02441306 · ended Jan 21, 2020 · Demand increase for the drug.
Resolved
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Aug 30, 2019 · Requirements related to complying with good manufacturing practices.
Avoided
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Feb 9, 2018 · Delay in shipping of the drug.
Resolved
JENCYCLA
0.35MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02441306 · ended Dec 11, 2017 · Demand increase for the drug.
Showing 12 of 13 reports. All reports are on file with Health Canada.
What's happening
Norethindrone is currently affected by an active shortage report filed with Health Canada by GLENMARK PHARMACEUTICALS CANADA INC..
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Norethindrone is classified under “HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE” (ATC G03AC).
Recent changes
No changes recorded yet.
Common questions
What is Norethindrone used for?
A progestin hormone used for birth control and menstrual conditions.
When will Norethindrone be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Norethindrone in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.